Furthermore, MYB is considered a potential target for anticancer therapy [66] for acute myeloid leukemia (AML), T-cell acute leukemia (T-ALL), adenoid cystic carcinoma (ACC), and other types of cancer [67,68], and also for other diseases like inflammatory osteoclast formation and bone resorption [69]. This evidence concerns the gene MYB and adrenal cortex carcinoma.